Related references
Note: Only part of the references are listed.Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage
Stephanie Raymond et al.
JOURNAL OF CLINICAL VIROLOGY (2010)
Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-Tropic HIV-1 Infection
David A. Cooper et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
International Network for Comparison of HIV Neutralization Assays: The NeutNet Report
Eva Maria Fenyo et al.
PLOS ONE (2009)
Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes
Carolina Garrido et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2008)
Subgroup analyses of Maraviroc in previously treated R5 HIV-1 infection
Gerd Faetkenheuer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Maraviroc for previously treated patients with R5 HIV-1 infection
Roy M. Gulick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Correlation between a phenotypic assay and three bioinformatic tools for determining HIV co-receptor use
Eva Poveda et al.
AIDS (2007)
Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies
Pierre Delobel et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2007)
Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism
Jeannette M. Whitcomb et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1
J. Garcia-Perez et al.
JOURNAL OF MEDICAL VIROLOGY (2007)
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
G Fätkenheuer et al.
NATURE MEDICINE (2005)
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
P Dorr et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Structure of an unliganded simian immunodeficiency virus gp120 core
B Chen et al.
NATURE (2005)
Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences
MA Jensen et al.
JOURNAL OF VIROLOGY (2003)
A new perspective on V3 phenotype prediction
S Pillai et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2003)
Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors
B Labrosse et al.
JOURNAL OF VIROLOGY (2003)
Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop
NG Hoffman et al.
JOURNAL OF VIROLOGY (2002)
Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay
V Trouplin et al.
JOURNAL OF VIROLOGY (2001)
Share Paper
